Breast Cancer Coverage from Every Angle
Editor:
William J. Gradishar, MD, FACP, FASCO
Advertisement
Advertisement

Available Clinical Trials

Evaluating CX-2009 Safety and Antitumor Activity and as Monotherapy or in Combination with CX-072 in Breast Cancer
Circulating Tumor DNA Enriched, Genomically Directed Post-Neoadjuvant Trial for Residual Triple Negative Breast Cancer
A Phase II Circulating Tumor Post-Neoadjuvant Trial For Patients With Residual Triple Negative Breast Cancer
City of Hope, Triple-Negative Breast Cancer
Dana-Farber Cancer Institute - Breast Oncology Clinical Trial Finder
Duke Cancer Institute
Fox Chase Cancer Center
Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
Huntsman Cancer Institute at the University of Utah
Mayo Clinic Cancer Center
Memorial Sloan Kettering Cancer Center
Moffitt Cancer Center
Phase 2 Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative and Triple-Negative Breast Cancer
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Roswell Park Cancer Institute
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
The University of Texas MD Anderson Cancer Center
UC San Diego Moores Cancer Center
UCSF Helen Diller Family Comprehensive Cancer Center
University of Colorado Cancer Center
University of Michigan Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Vanderbilt-Ingram Cancer Center
Yale Cancer Center/Smilow Cancer Hospital
Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.